# Schinus molle

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/schinus-molle
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Peruvian pepper tree, Molle, California pepper tree, Pink peppercorn tree, False pepper, Pepper tree, American pepper, Mastic tree, Aguaribay, Aroeira-salsa, Pirul

## Overview

Schinus molle, the Peruvian pepper tree, contains bioactive terpenes including α-phellandrene, β-myrcene, and phenolic compounds that exert [antimicrobial](/ingredients/condition/immune-support) and antiparasitic effects primarily through membrane disruption and interference with [mitochondrial function](/ingredients/condition/energy) in pathogens. Its essential oil and ethanolic extracts have demonstrated activity against drug-resistant Candida albicans and Trypanosoma cruzi, the protozoan responsible for Chagas disease.

## Health Benefits

• Antifungal activity against resistant Candida albicans (preliminary evidence: 100% ethanolic extract showed 5.67 ± 4.509 mm inhibition, p=0.038)
• Anti-parasitic effects against Trypanosoma cruzi, the causative agent of Chagas disease (preliminary evidence: IC50 values demonstrated in vitro)
• [Antimicrobial](/ingredients/condition/immune-support) activity against E. coli and S. aureus bacteria (preliminary evidence: in vitro studies only)
• Antiproliferative effects on HL-60 leukemia cells (preliminary evidence: EC50 <30 µg/mL in vitro)
• Quorum sensing inhibition and antivirulence properties against S. aureus (preliminary evidence: in silico docking studies)

## Mechanism of Action

The terpene-rich essential oil of Schinus molle, particularly α-phellandrene and β-myrcene, disrupts fungal cell membrane integrity by intercalating into phospholipid bilayers, increasing permeability and causing cellular leakage in Candida albicans. Against Trypanosoma cruzi, phenolic compounds and terpenoids are hypothesized to inhibit trypanothione reductase, an enzyme critical to the parasite's redox defense system that has no human homolog. Additionally, flavonoids present in the leaf and bark extracts may inhibit [reactive oxygen species](/ingredients/condition/antioxidant) scavenging pathways unique to the parasite, contributing to antiprotozoal cytotoxicity.

## Clinical Summary

Current evidence for Schinus molle is limited to in vitro and preliminary laboratory studies; no robust human clinical trials have been published. One in vitro antifungal study demonstrated a 5.67 ± 4.509 mm zone of inhibition against resistant Candida albicans using a 100% ethanolic extract at a statistically significant threshold (p=0.038), though the wide standard deviation suggests variable potency. Antiparasitic effects against Trypanosoma cruzi have been quantified via IC50 values in cell-based assays, but selectivity indices and safe concentration windows in human tissue have not been established. The overall evidence base is classified as preliminary, and extrapolation of these findings to clinical recommendations for humans is not currently supported.

## Nutritional Profile

Schinus molle (Peruvian pepper tree/molle) is not a significant dietary source of macronutrients but contains a diverse array of bioactive phytochemicals. Proximate composition of dried berries: moisture ~8-12%, crude fat ~18-25% (primarily in the essential oil fraction), crude protein ~5-8%, total carbohydrates ~40-55%, crude fiber ~15-20%, ash ~3-5%. Key bioactive compounds include: (1) Essential oil constituents — α-phellandrene (20-40% of essential oil), β-phellandrene (5-15%), α-pinene (5-20%), limonene (3-10%), myrcene (2-8%), and caryophyllene (2-6%), with total essential oil yield of approximately 1.5-4% from dried plant material; (2) Phenolic compounds — gallic acid, caffeic acid, quercetin, kaempferol, and rutin, with total phenolic content reported at approximately 15-45 mg GAE/g dry weight in ethanolic extracts; (3) Terpenes and terpenoids — sabinene, terpinen-4-ol, and α-terpineol; (4) Flavonoids — total flavonoid content approximately 5-20 mg QE/g dry weight; (5) Tannins — hydrolyzable and condensed tannins present at approximately 2-8% dry weight; (6) Triterpenes — oleanolic acid and ursolic acid identified in leaf extracts. Mineral content is modest: calcium (~200-400 mg/100g dried material), potassium (~300-500 mg/100g), magnesium (~50-100 mg/100g), iron (~3-8 mg/100g), and zinc (~1-3 mg/100g). Vitamin C has been reported in fresh plant parts (~10-30 mg/100g fresh weight). Bioavailability is limited by the presence of tannins, which may reduce mineral absorption; essential oil compounds are highly lipophilic, with bioavailability enhanced by lipid-containing matrices. Most nutritional data is derived from phytochemical analyses rather than standardized nutritional studies; values vary considerably by geographic origin, plant part (leaves, bark, fruit, resin), and extraction method.

## Dosage & Preparation

No clinically studied dosage ranges exist for humans. In vitro studies used concentrations of 25-100% for ethanolic extracts and IC50 values of ~100-1000 µg/mL for anti-parasitic activity. No standardization protocols have been established for human use. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Schinus molle is generally considered potentially allergenic, particularly in individuals sensitive to other members of the Anacardiaceae family such as poison ivy, mango, or cashew, due to shared urushiol-like resin compounds. Topical contact with the bark or resin has been associated with contact dermatitis, and ingestion of large quantities of the berries has been reported to cause gastrointestinal irritation, nausea, and headache in sensitive individuals. No formal drug interaction studies exist, but given its [antimicrobial](/ingredients/condition/immune-support) terpene content, caution is warranted when combining with immunosuppressants or antifungal medications due to possible additive or antagonistic effects. Pregnant and breastfeeding women should avoid therapeutic use, as uterotonic properties have been attributed to the plant in traditional ethnobotanical literature and no human safety data exists.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Schinus molle. All available evidence is limited to in vitro and preclinical studies, including an antifungal study (PMID: 41140939) showing activity against resistant Candida albicans, though less effective than fluconazole.

## Historical & Cultural Context

Schinus molle has been used in traditional Peruvian and Latin American medicine for various ailments, particularly as an antiparasitic for protozoal infections like Chagas disease. Historical use spans indigenous Andean systems, with documentation as a medicinal tree for treating protozoa (Leishmania, Plasmodium), helminths, and general health issues.

## Synergistic Combinations

Echinacea, Andrographis, Cat's Claw, Pau d'Arco, Oregano Oil

## Frequently Asked Questions

### Does Schinus molle kill Candida albicans?

In vitro, a 100% ethanolic extract of Schinus molle produced a 5.67 ± 4.509 mm zone of inhibition against resistant Candida albicans strains at a statistically significant level (p=0.038). The mechanism likely involves terpene-mediated disruption of the fungal cell membrane. However, this is preliminary laboratory data only, and no human clinical trials have confirmed antifungal efficacy or established a therapeutic dose.

### Can Schinus molle treat Chagas disease?

Extracts of Schinus molle have shown measurable IC50 activity against Trypanosoma cruzi, the protozoan parasite that causes Chagas disease, in in vitro assays. Phenolic compounds and terpenoids in the extract are thought to interfere with the parasite's trypanothione reductase enzyme system. There are currently no human clinical trials testing Schinus molle as a treatment for Chagas disease, and it should not be used as a substitute for approved antiparasitic drugs such as benznidazole or nifurtimox.

### What are the active compounds in Schinus molle?

The primary bioactive compounds in Schinus molle include monoterpenes such as α-phellandrene, β-myrcene, and limonene in the essential oil, along with flavonoids, tannins, and phenolic acids concentrated in the leaves and bark. Triterpenoids including masticadienonic acid have also been isolated from the resin. The relative concentrations of these compounds vary by plant part, geographic origin, and extraction method, which contributes to variability in reported biological activity.

### Is Schinus molle safe to take as a supplement?

No standardized supplement form of Schinus molle has been approved by regulatory agencies such as the FDA or EMA, and no human safety trials have established a tolerated dose range. Allergic reactions including contact dermatitis are documented, particularly in those with Anacardiaceae family hypersensitivity. Gastrointestinal side effects such as nausea and irritation have been reported with berry ingestion, and traditional sources indicate potential uterotonic effects, making it contraindicated in pregnancy.

### What part of the Schinus molle plant is used medicinally?

Different parts of the Schinus molle tree have distinct medicinal applications: the leaves and their essential oil are most commonly studied for antimicrobial and antiparasitic properties, while the bark has been used in traditional Andean medicine as an anti-inflammatory and wound-healing agent. The resin, known as American mastic, contains triterpenoids with documented antimicrobial properties. The pink berries are used as a spice substitute for black pepper but contain sufficient alkaloids and resins to cause gastrointestinal irritation in large amounts.

### Does Schinus molle interact with antimicrobial or antiparasitic medications?

Schinus molle exhibits its own antimicrobial and antiparasitic properties, which raises potential for additive or synergistic effects when combined with conventional antiparasitic agents like benznidazole (used for Chagas disease) or antifungal medications. No specific drug-drug interaction studies have been published, making it advisable to consult a healthcare provider before combining Schinus molle supplements with prescription medications for infections or parasitic diseases. The possibility of enhanced therapeutic effects or altered drug metabolism cannot be ruled out without clinical evidence.

### What is the evidence quality for Schinus molle's antimicrobial benefits compared to its traditional use?

Current evidence for Schinus molle's antimicrobial activity is limited to in vitro laboratory studies showing inhibition of E. coli, S. aureus, and Candida albicans, with no published human clinical trials. While traditional medicine has used Schinus molle for centuries in South America, the gap between preliminary in vitro data and proven clinical efficacy remains substantial. More rigorous controlled studies in humans would be needed to validate dosing, efficacy, and safety for treating bacterial or fungal infections.

### Who should avoid Schinus molle supplements based on current safety data?

Pregnant and nursing women should avoid Schinus molle due to insufficient safety data in these populations, particularly given its antimicrobial and antiparasitic properties which may affect fetal development or breast milk composition. Individuals with allergies to the Anacardiaceae family (which includes cashews and pistachios) should exercise caution, as cross-reactivity is possible. Patients taking immunosuppressive medications or those with compromised immune systems should consult a healthcare provider, since Schinus molle's immune-stimulating antimicrobial activity may create unintended interactions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*